A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults
收藏DataCite Commons2025-11-04 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00011811/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This a phase 1 first-in-human clinical trial to evaluate the safety, tolerability, and immunogenicity of BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in up to 60 healthy adult HIV-uninfected volunteers.
提供机构：
Vivli
创建时间：
2025-10-01
